Single-center clinico-genomic analysis of KIT mutated melanomas and clinical outcomes with tyrosine kinase inhibitor treatment
Authors:
- Carl Maximilian ThielmannCTCarl Maximilian Thielmann
- Luisa RichterLRLuisa Richter
- Henry Karl TapkenHTHenry Karl Tapken
- Johanna Andrea SeierJSJohanna Andrea Seier
- Lisa SchielkeLSLisa Schielke
- Jan SternbergJSJan Sternberg
- Julia KretzJKJulia Kretz
- Inga MöllerIMInga Möller
- Antje SuckerASAntje Sucker
- Annette PaschenAPAnnette Paschen
- Lennart Ocker-SergerLOLennart Ocker-Serger
- Frederik KreftingFKFrederik Krefting
Open Access
- 30 June 2026
- journal article
- Published by Elsevier in EJC Skin Cancer
- Vol. 4
Abstract
No abstract availableFunding Information
- Universitätsklinikum Essen
- Universität Duisburg-Essen
This publication has 28 references indexed in Scilit:
- Clinical and genomic correlates of imatinib response in melanomas with KIT alterationsBritish Journal of Cancer, 2022
- Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanomaESMO Open, 2022
- NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsEuropean Journal of Cancer, 2021
- c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysisEuropean Journal of Cancer, 2021
- Passenger Hotspot Mutations in CancerCancer Cell, 2019
- KIT as an Oncogenic Driver in Melanoma: An Update on Clinical DevelopmentAmerican Journal of Clinical Dermatology, 2019
- Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilitiesThe Journal of Pathology, 2018
- MelanomaThe Lancet, 2018
- Intratumor and Intertumor Heterogeneity in MelanomaTranslational Oncology, 2017
- KIT as a Therapeutic Target in Metastatic MelanomaJAMA, 2011